The effects of in v i w exposure to phenobarbital (PB) on hepatic gap junctional intercellular communication (GJIC) and conncxin protein expression in Sprague-Dawley rats were examined by in vivolirn virro dye-transfer assay, immunohistochemical staining, and by Western blot analysis. PB (50 mgkg) was administered orally once a day for up to 6 wk. The average size of the dye spread after injection of Lucifer Yellow decreased at week 1 and remained at the same level until \veek 6. The area and number of connexin 32 (Cx32) spots pcr hcpatocyte in the central zone of liver lobules decreased from week 1 to week 6, but no change of Cx32 spots in thc pcriphcral zone was obscrvcd. Thc average area and number of connexin 26 (Cx26) spots per hepatocytes showed no clear change through thc cxpcrimcntal pcriods. Thc dccrcascd level of Cx32 protein in plasma membranes was observed in the PB group. These results suggest that PB, a liver tumor-promoting agent, inhibits hepatic GJIC in vivo in rats and that aberrant Cx32 protein expression and/or localization may be responsible for this effect.
INTRODUCTION
Gap junctional intercellular communication (GJIC) is considered to play an important role in carcinogenesis. A recent review of the ability of chemicals with tumor-promoting or tumor-inhibiting activity to modulate GJIC reports that more than 100 substances have been shown to inhibit GJIC (1) . The inhibition of GJIC appears to be the most common property of chemicals with tumor-promoting activity; however, phenobarbital (PB), a liver tumor promoter (2, lo), has shown mixed results (negative andlor positive) in iit vitro assays (1) . It was reported that PB (0.05% in diet) diminished the total area and size of rat hepatocyte gap junctions by freeze-fracture analysis in vivo (12) . The level of gap junction protein mRNA in rat liver was observed to be markedly reduced at 4 and 11 wk of PB exposure (0.1% in drinking water) (7). However, there have been few studies that examine the hepatic gap junctional functions of rats exposed to PB iii vivo (5). We have studied the effect of DDT on hepatic GJIC in rats and clearly demonstrated that DDT inhibited hepatic GJIC and caused aberrant connexin 32 (Cx32) and connexin 26 (Cx26) protein expression iii vivo (13) . This study was conducted to demonstrate the inhibition of hepatic GJIC in rats exposed to PB-iiz vivo and compare these results with the effects of DDT In the present study, the effects of PB on hepatic GJIC of rats treated orally with PB (50 mglkgiday) for up to 6 wk were examined by iit vivoiiit vitro dye-transfer assay using freshly removed liver slices. Localization of the hepatic gap junction proteins, Cx32 and Cx26, and protein levels of 'Address correspondence to: Dr. Sciichi Ito, Nippon Expenmcntal Medical Research Institute Co.. Ltd., 416 Nakasatomi Haruna-machi, Gunma-gun. Gumna 370-33. Japan. 'Present address: Kyoto Pharmaceutical University. 5 Nakauchi-cho. Goryo. Yamashina-ku. Kyoto 607. Japan. Cx32 were also studied by immunohistochemical staining and Western blot analysis. Furthermore, hepatocyte proliferation was checked by immunohistochemical staining of proliferating cell nuclear antigen (PCNA).
MATERIALS AND METHODS

A i t i i d s niid
Treatineitt. Six-week-old male Sprague-Dawley rats (Charles River Japan Inc., Japan), weighing 176-199 g at the beginning of the study, were used. PB (50 mg/kg/day) was administered orally once a day; 0.05% or 0.1% PB in the diet or drinking water was used in the studies referenced (2, 7, 12) . PB at 0.05% in the diet is equivalent to about 25 mgikg/day when % is converted into mgkgiday. A dose of 50 mgikg/day was selected to obtain more clear effects. Three animals per group were euthanized at weeks 0 (control group), 1, 2, 4, and 6 after the experiment began.
The animals were housed 3/cage, at 23 ? 2"C, a relative humidity of 55 2 1096, and with a 12-hr lightidark cycle. Animals were fed a CRF-1 pellet diet (Charles River Japan) and tap water ad libitum. After autopsy, wet liver weights were measured. Each liver was sectioned into 3 adjacent parts from the left lateral lobe; one was used for the iii vivoiiii vitro dye-transfer assay, another 'was fixed in 10% neutral buffered formalin solution for 24 hr and prepared as paraffin sections for hematoxylin and eosin (H&E) staining and PCNA immunohistochemical staining, and the remainder was frozen in liquid nitrogen for Cx32 and Cx26 immunohistochemical staining and Western blot analysis of Cx32.
Iii VivolIii Vitro Dye-Transfer Assay of GJIC iii Fresh Liver Slices. GJIC was measured by direct microinjection dye-transfer assay of liver freshly removed from rats. freshly isolated liver were prepared using a double-bladed knife. Then 10-20 injections/slice of 10% Lucifer Yellow CH (Aldrich Chemical Co., USA) in 0.3 M lithium chloride were made in Williams' medium E (Flow Laboratories, Scotland), with an approximately constant-flow rate of the dye into the liver slice maintained by using a 5242 microinjector and 5 170 micromanipulator (Eppendorf, Germany) under a Diaphot-TMD fluorescence microscope (Nikon, Japan). After 10 min, the excess dye that did not enter the cells was removed by washing the samples 3 times with medium. The injected liver slices were embedded in OCT compound (Miles, Inc., USA) and frozen by liquid nitrogen, after which they were cut into 10-pm semiserial sections with a 2800 Frigocut cryostat (Leica, Germany), dried, soaked in xylene for a few seconds, and mounted in Diatex (AB Wilh, Becker, Sweden). The slides were examined under a New Vanox AHBS light microscope with AH2-FL fluorescence equipment (Olympus). For examination of the GJIC permeability in the liver, 20 injected spotdgroup were selected and photographed; the photographs were used for subsequent measurement of dye-transfer surface area by computerized image analysis, using an image processor for analytical pathology (IPAP; Sumika Technos, Takarazuka, Japan). Each injected spot that had a maximum area in semiserial sections was selected for examination.
Iiiimrrrroliistoclieriiicnl nitd Morpltoritetric Stirdy. The frozen liver was cut into 5-pm sections with the cryostat for Cx32 and Cx26 immunohistochemical staining. Sections were then fixed in acetone at -20°C for 5 min and dried. The dried sections were successively incubated with rabbit anti-Cx32 antiserum (1/2,000 dilution) or a rabbit polyclonal antibody against a Cx26-specific peptide (amino acid residues 101-1 19) (1/200 dilution) for 1 hr, and with biotinylated goat anti-rabbit IgG (1/200 dilution, Vector Laboratory, Inc., USA) for 1 hr, and then with fluorescentric streptavidin (1/30 dilution, Vector) for 30 min in the dark. The sections were examined by light microscopy with fluorescence equipment, and 3 photographs were taken at the central or peripheral zones (total of 6 per animal) for Cx32 and Cx26. From the photographs, the number of Cx32-and Cx26-positive spots per hepatocyte and the area per Cx32-and Cx26-positive spot were measured by an IPAP system. Approximately 150 cells/animals were counted in the areas within about 300 pm of the central vein or portal vein for the central zone or peripheral zone, respectively.
-For PCNA immunostaining, 5-pm paraffin sections were successively incubated with NCL-PCNA mouse monoclonal antibody (1/100 dilution, Novocastra Laboratories Ltd., UK) for 30 min, with biotinylated horse anti-mouse IgG (1/200 dilution, Vector) for 30 min, and with ABC complex (Vector) for 1 hr, and stained with 3, 3'-diaminobenzidine tetrahydrochloride (Nacalai). The numbers of nuclei and PCNA-positive nuclei were counted under the microscope by an IPAP system. Approximately 1.000 nuclei per animal were counted in randomly selected areas.
Western Blot Aiinlysis. Rat liver gap junctions were isolated from alkali-extracted rat liver plasma membranes from frozen rat livers by the procedure described by Hertzberg (4). The concentration of protein was determined by BCA protein assay reagent (Pierce, USA). Samples (3 pg) were analyzed on 15% sodium dodecyl sulfate-polyacrylamide gels and transferred to nitrocellulose membranes. Antibody binding was determined using rabbit anti-Cx32 antiserum (1/10,000 dilution) and a blotting detection kit for rabbit antibodies (Amersham, UK).
RESULTS
Slight decreases in mean body weight in the PB group were observed at weeks 4 and 6, but there were no statistical differences from the control group. Increased absolute and relative liver weights were observed in the PB group from week 1, and there were statistical differences from the control group at weeks 1 and 6. In histopathological examinations, centrilobular hepatocellular hypertrophy was observed in the PB group.
In the in vivo/in vitro dye-transfer assay, decreases in the area of the dye spread were observed at week 1 in the PB group and remained at the same level until week 6. Statistical differences from the control group were observed at weeks 4 and 6 ( Figs. 1 and 4A) .
Immunohistochemical examination revealed that the Cx32 spots were uniformly distributed in hepatocytes of Week of e x p e r i m e n t the hepatic lobules in the control group. In the PB group, the area and number of Cx32 spots per hepatocyte in the central zone of the hepatic lobules decreased at weeks 1, 2, 4, and 6 with statistical differences from the control group; however, no changes in Cx32 spots were observed in the peripheral zone of the hepatic lobules at any intervals ( Figs. 2 and 4B, C) . Cx26 spots in the control group were prominent in the peripheral zone and almost absent in the central zone of the hepatic lobules. In the PB group, no clear changes in the area and number of Cx26 spots were observed in both the central and peripheral zones throughout the study periods ( Figs. 3 and  5A) .
The number of PCNA-positive nuclei in the control group showed a tendency to decrease during aging. In contrast, in the PB group, the number of PCNA-positive nuclei increased to the maximal level at week 2 (without statistical difference), and the effect remained at week 6 (with statistical difference) (Fig. 5B) . PCNA-positive nu-clei were prominent in the midzonal hypertophic hepatocytes in the PB group (data not shown).
In the Western blot analysis, anti-Cx32 antibody specifically detected a 27-kDa protein. A smaller amount of Cx32 protein was observed in the PB group at week 1 but levels recovered by week 6 (Fig. 6) .
Discussio~
This study clearly demonstrated that PB had inhibitory effects on hepatic GJIC of rats from week 1 to week 6 iiz viva The immunohistochemical staining indicated that the area and number of Cx32 spots per hepatocyte in the central zone of the liver lobes decreased with PB exposure during the 6 wk. However, there were no changes in either the Cx32 spots in the periportal zone of the liver lobes or in the Cx26 spots in all lobes following exposure to PB. The changes in (2x32 expression in the central zone of the liver lobes seemed to parallel the changes in GJIC. These results suggest that GJIC may be modified by Cx32 but not by Cx26 during exposure to PB. Krutovskikh et a1 (5) reported that nearly total disappearance of Cx26 from cells was observed in the central zone of the hepatic lobules after treatment with tumor-promoting agents including PB. Our results demonstrate that Cx26 was prominent in the peripheral zones and almost absent in hepatocytes located near the central vein in the control rat liver, in accordance with findings in previous reports (13, 11) . The reasons for the discrepancy in the distribution of Cx26 between this study and Krutovskikh's are unknown, but this may be due to the fixation methods, the immunostaining methods, or antibodies used.
Western blot analysis showed that the level of Cx32 protein was decreased in the PB group at week 1 but recovered at week 6. The reason for this recovery is unknown, but the results suggest that aberrant localization of Cx32, rather than a lower level of its protein amount, is responsible for inhibition of GJIC by PB. It has been reported that the level of Cx32 mRNA in rat liver is markedly reduced at 4 and 11 weeks of PB exposure (7).
In the present study, Cx32 protein levels were decreased in the PB group. In the case of DDT, Cx32 protein levels were also decreased, although no changes in the levels of Cx32 mRNA were observed by Northern blot analysis (13) . These results suggest that PB and DDT act to inhibit rat hepatic GJIC through different mechanisms.
A recent study indicates that Cx32 expression apparently correlates with cellular independence and growth advantage during tumor progression in the liver (14) . Chronic administration of PB, while maintaining a decreased level of Cx32 protein, resulted in no increase in DNA synthesis, suggesting that PB produces no effect on Cx32 expression by DNA through such synthesis (9) . In the present study, decreased Cx32 was observed in the central zone in the PB-treated group; however, increased cell proliferation was prominent in the mid-zone. It has been reported that hepatocytes from the peripheral zones respond more strongly to epidermal growth factor or hepatocyte growth factor than do hepatocytes from the central zones (3, 15) . These inherent differences in the growth potential of hepatocytes from different lobular localization may contribute to enhanced growth of hepatocytes in the midzones of the liver of rats exposed to PB. Therefore, a tendency to increase cell proliferation was observed in PB-treated rats, possibly correlating with the inhibition of GJIC without a clear interrelationship of Cx32 and cell proliferation in lobular distribution.
In a previous report (13) , DDT inhibited GJIC from week 1 to week 4 in rats, but the inhibition recovered by week 6. It is, however, noteworthy that the inhibition of GJIC by PB continued until week 6. This fact is coincident with the fact that a single application of PB to cocultures of hepatocytes has a transient effect, whereas a repeated application for several weeks leads to a constant inhibition of GJIC (50%) (8). This continuous inhibition of GJIC may play an important role in hepatocarcinogenesis by PB.
In conclusion, inhibition of hepatic GJIC or aberrant localization of Cx32 could be used as an endpoint to detect tumor-promoter activity of in vivo-applied agents.
